Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome Clinical research trials and A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome. A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome clinical trial. Subjects typically recieve the finest healthcare available for their A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome



A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

For Condition: HIV Infections,HIV Wasting Syndrome
Status: Completed
Sponsor(s): Celgene Corporation ,
Synopsis: To evaluate the safety, antiviral and anti-TNF-alpha activity, and preliminary efficacy of thalidomide in reducing weight loss in patients with HIV wasting syndrome.
Details: Patients are randomized to receive either thalidomide at 1 of 2 doses or placebo for 8 weeks. Patients who respond may continue in double-blinded treatment for an additional 4 weeks; nonresponding patients may receive thalidomide for up to 4 weeks. Per amendment, patients may receive thalidomide for more than 12 weeks on a compassionate basis.
Eligibility:
Study Type:
  Interventional, Treatment, Double-Blind, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Primary prophylaxis for opportunistic infections (if AFB blood culture negative). - Chronic suppressive therapy (maintenance) for opportunistic infections OTHER THAN Mycobacterium avium Complex (MAC). Patients must have: - Documented HIV infection. - Wasting syndrome. - Negative blood PCR for acid-fast bacteria (AFB) or a negative AFB blood culture within 48 days prior to study entry. - No active opportunistic infection requiring systemic therapy within 6 weeks prior to study entry. - Life expectancy of at least 6 weeks. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Chronic diarrhea (five or more unformed stools per day). - Peripheral neuropathy of grade 2 or worse. - Requirement for tube feeding or intravenous feeding. - Any disorder associated with moderate to severe edema (e.g., cirrhosis, nephrosis, congestive heart failure). - Inability to ingest at least a maintenance diet based on present weight. - Any condition that precludes study participation. - Not under the care of a primary physician. Concurrent Medication: Excluded: - Chronic suppressive therapy (maintenance) or secondary prophylaxis for Mycobacterium avium Complex (MAC) (suppressive therapy for other opportunistic infections is allowed). Concurrent Treatment: Excluded: - Radiotherapy. Patients with the following prior conditions are excluded: - Any neoplasms other than non-medicated (i.e., not receiving systemic or intralesional chemotherapy) Kaposi's sarcoma within 1 month prior to study entry. - Prior intolerance to thalidomide. Prior Medication: Excluded: - ddC within 1 month prior to study entry. - Acute systemic therapy for opportunistic infections within 6 weeks prior to study entry. - Agents that are anabolic, catabolic, or immunomodulatory (including interferons, megestrol, dronabinol, oxandrolone, growth hormone, systemic corticosteroids, and pentoxifylline) within 30 days prior to study entry. Prior Treatment: Excluded: - Radiotherapy within 6 weeks prior to study entry. Required ONLY IF patient is on antiretroviral therapy: - Stable regimen of AZT or ddI for at least 1 month prior to study entry. Active drug abuse within 3 months prior to study entry.
Total Enrollment: 75

Location and Contact Information:

Advanced Research Management
Seattle,  Washington,  981225314
United States
 

Rockefeller Univ
New York City,  New York,  10021
United States
 

Kansas City AIDS Research Consortium
Kansas City,  Missouri,  64111
United States
 

AIDS Community Research Consortium
Redwood City,  California,  940631633
United States
 

Community Research Initiative of South Florida
Coral Gables,  Florida,  33146
United States
 

San Francisco Gen Hosp
San Francisco,  California,  94110
United States
 

Saint Michael's Med Ctr
Newark,  New Jersey,  07102
United States
 

Kaiser Permanente Med Ctr
San Francisco,  California,  94115
United States
 

Thomas Jefferson Med College
Philadelphia,  Pennsylvania,  19107
United States
 

Gottlieb Med Group
Sherman Oaks,  California,  91403
United States
 

George Washington Univ Med Ctr
Washington D.C.,  District of Columbia,  20037
United States
 

Marin County Specialty Clinic
Greenbrae,  California,  94904
United States
 

UCSD Med Ctr - Owen Clinic
San Diego,  California,  921038681
United States
 


Additional Information:
Study ID Numbers:
  230A;  W-001
Study Start Date: 
Record last reviewed: July 1997
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002127

Other Hiv Wasting Syndrome Studies:
1. A Study of Dideoxycytidine Plus Zidovudine in the Treatment of AIDS or Advanced AIDS Related Complex (ARC)

2. The Safety and Effectiveness of 1592U89 Plus 141W94 Plus DMP 266 in Patients with HIV Who Developed a Resistance to Protease Inhibitors

3. The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease

4. Treatment of Advanced AIDS Patients with Dextrin Sulfate

5. (Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC

Related Studies:

Other HIV Wasting Syndrome Clinical Trials
Other District of Columbia Clinical Trials
Other Washington D.C. Clinical Trials

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

Modify your Search

  Other HIV Wasting Syndrome Clinical Trials
  Other District of Columbia Clinical Trials
  Other Washington D.C. Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103